# EGFR Osimertinib Resistance in NSCLC
### Third-generation EGFR inhibitor acquired resistance mechanisms

---

**Run ID:** `run_268916424e63`  
**Status:** `completed`  
**Confidence:** `0.81`  
**Agent steps:** 141  
**Tool calls:** 58  
**Evidence items:** 32  
**Experiments proposed:** 6  

---


Run: `run_268916424e63`
Status: `completed`
Confidence: `0.81`
Confidence interpretation: `moderate`

## Candidate Hypothesis

EGFR remains an early or insufficiently established hypothesis for non-small cell lung cancer; claims require explicit validation and stronger public evidence. Relevant clinical literature titles include: Immunotherapy for TKI-resistant, EGFR L858R-mutated non-small cell lung cancer: a systematic review and meta-analysis of randomized and single-arm studies.; Amivantamab plus chemotherapy vs. chemotherapy as first-line treatment in Chinese mainland patients with EGFR exon 20 insertion non-small cell lung cancer: Subgroup analysis of the randomized PAPILLON trial.. The remaining scientific work is to resolve mechanism details, response or resistance biology, safety liabilities, and patient-selection strategy; this is not a claim that a new target has been discovered.

## Scientific Assessment

- Treat as speculative until public target-disease evidence is retrieved.
- The disease-target rationale is biologically plausible when live/public evidence links EGFR to non-small cell lung cancer through disease association, pathway, or mechanism records.
- The current claim should remain pathway-level: evidence supports target and mechanism grounding, not clinical efficacy for any intervention unless direct clinical evidence is cited.
- Relevant clinical literature titles include: Immunotherapy for TKI-resistant, EGFR L858R-mutated non-small cell lung cancer: a systematic review and meta-analysis of randomized and single-arm studies.; Amivantamab plus chemotherapy vs. chemotherapy as first-line treatment in Chinese mainland patients with EGFR exon 20 insertion non-small cell lung cancer: Subgroup analysis of the randomized PAPILLON trial..
- Candidate molecules or interventions are prioritization leads only; potency, selectivity, exposure, safety, and disease-model response must be tested.

## Key Scientific Claims

- Amivantamab plus lazertinib and osimertinib produce distinct acquired resistance mechanism profiles in first-line EGFR-mutated NSCLC, as reported in the MARIPOSA trial.
- Immunotherapy demonstrates limited clinical activity in TKI-resistant, EGFR L858R-mutated NSCLC based on a systematic review and meta-analysis of randomized and single-arm studies.
- Compound EGFR mutations classified as PACC mutations show greater responsiveness to second-generation than third-generation TKIs, indicating that mutation subtype determines optimal TKI generation.
- Amivantamab plus chemotherapy improves outcomes over chemotherapy alone as first-line treatment in EGFR exon 20 insertion NSCLC, as demonstrated in the PAPILLON trial subgroup analysis in Chinese mainland patients.

## Objective Classification

- Primary task: `therapeutic_reasoning`
- Domain: `biomedical_omics`
- Risk level: `high`
- Capabilities: public_biomedical, tooluniverse, clawinstitute_board, txagent, safety_reviewer, abstention_policy

## Case Capability Plan

**Mechanism branches to resolve:**
- `on_target_variant`: Variant-level on-target resistance
- `copy_number`: Copy-number driven resistance
- `rtk_bypass`: RTK or fusion bypass signaling
- `mapk_pi3k_reactivation`: MAPK or PI3K pathway reactivation
- `cell_state`: Cell-state plasticity
- `lineage_transformation`: Lineage or histologic transformation
- `anatomic_pharmacologic`: Anatomic or pharmacologic resistance
- `safety_translation`: Safety and translational feasibility

**Validation assays requested by the case:**
- ctDNA clone structure and cis/trans phasing
- paired pre/post-treatment biopsy profiling
- single-cell or spatial cell-state profiling
- fusion and copy-number profiling

**Capabilities exercised:** case_compilation, public_evidence_retrieval, claim_graph, evidence_coverage_matrix, experiment_gate_scoring, replayable_provenance

## Evaluation Criteria

Score: `0.852` (23/27 points)
- [met] Identifies the primary biomedical entities and objective scope.
- [met] Separates direct evidence from indirect or planning-only evidence.
- [met] States uncertainty and avoids unsupported clinical efficacy or safety claims.
- [met] Includes limitations and concrete validation experiments.
- [met] Reviews intervention-specific safety, contraindication, and translation gaps.
- [met] Checks omics context, cell type, dataset compatibility, and analysis validity.
- [met] Explains target-disease relevance without overstating causality.
- [gap] Answers the specific user objective rather than a generic biomedical prompt.

## Abstention Assessment

- Required: `False`
- Allowed output: candidate hypothesis with explicit limitations

## Biomedical Validation Controls

- BioTruth critic: `weak_support` (score: `80.4`)
- Evidence hierarchy: `32` evidence items; `15` high-tier items; score `65.62`
- Contradiction search attempted: `True`; findings `11`
- Abstention policy decision: `tentative_only` with required flag `False`
- Actionability profile: `moderate` with recommended decision `tentative_only`

## Scientific Strategy

**Readiness tier:** **Experiment ready (with gaps)** (65/100)
> experiment_ready_with_gaps: blocked mainly by claim_graph_evidence_gap (medium).

**Recommended next action:** `run_falsification_and_depth_pass`
> Readiness is experiment_ready_with_gaps; remaining gaps should be challenged before confidence increases.

**Evidence gaps identified:**

- 🟡 **claim_graph_evidence_gap** (medium): The claim graph still has unsupported evidence links: NCBI Gene, PubMed: AXL EMT bypass resistance EGFR inhibitor lung cancer single cell spatial transcriptomics, PubMed: fourth generation EGFR inhibitor BLU-945 BBT-176 clinical trial C797S.
  - Recommended tool: `tooluniverse_query_tool`
- 🟡 **reviewer_high_severity_concern** (medium): The hypothesis card contains a fundamental internal contradiction: it frames EGFR as 'early or insufficiently established' for NSCLC, yet the assembled evidence overwhelmingly demonstrates the opposite. EGFR has an OpenTargets association score of 0.888 for non-small cell lung carcinoma (the highest among 13,431 associated targets), multiple FDA-approved TKIs (osimertinib, erlotinib, gefitinib, afatinib, dacomitinib), an approved bispecific antibody (amivantamab), an ASCO Living Guideline (2026.
  - Recommended tool: `pubmed_literature_search_tool`
- 🟡 **evidence_relevance_noise** (medium): A material fraction of retrieved evidence was judged irrelevant to the claim boundary.
  - Recommended tool: `pubmed_literature_search_tool`

## Claim Graph

*6 claims mapped across 32 evidence items.*

### Claim claim_1 — `computational`
> EGFR remains an early or insufficiently established hypothesis for non-small cell lung cancer
- ✅ **Supporting:** ClinicalTrials.gov: non-small cell lung cancer BLU-945, ClinicalTrials.gov: non-small cell lung cancer EGFR, ClinicalTrials.gov: non-small cell lung cancer osimertinib, ClinicalTrials.gov: small cell lung cancer BLU-945, ClinicalTrials.gov: small cell lung cancer EGFR, ClinicalTrials.gov: small cell lung cancer osimertinib
- ⬜ **Gaps / irrelevant:** NCBI Gene, PubMed: AXL EMT bypass resistance EGFR inhibitor lung cancer single cell spatial transcriptomics, PubMed: fourth generation EGFR inhibitor BLU-945 BBT-176 clinical trial C797S, Reactome: EGFR

### Claim claim_2 — `computational`
> claims require explicit validation and stronger public evidence.
- ✅ **Supporting:** ClinicalTrials.gov: non-small cell lung cancer BLU-945, ClinicalTrials.gov: non-small cell lung cancer EGFR, ClinicalTrials.gov: non-small cell lung cancer osimertinib, ClinicalTrials.gov: small cell lung cancer BLU-945, ClinicalTrials.gov: small cell lung cancer EGFR, ClinicalTrials.gov: small cell lung cancer osimertinib
- ⬜ **Gaps / irrelevant:** NCBI Gene, PubMed: AXL EMT bypass resistance EGFR inhibitor lung cancer single cell spatial transcriptomics, PubMed: fourth generation EGFR inhibitor BLU-945 BBT-176 clinical trial C797S, Reactome: EGFR

### Claim claim_3 — `computational`
> Relevant clinical literature titles include: Immunotherapy for TKI-resistant, EGFR L858R-mutated non-small cell lung cancer: a systematic review and meta-analysis of randomized and single-arm studies.
- ✅ **Supporting:** ClinicalTrials.gov: non-small cell lung cancer BLU-945, ClinicalTrials.gov: non-small cell lung cancer EGFR, ClinicalTrials.gov: non-small cell lung cancer osimertinib, ClinicalTrials.gov: small cell lung cancer BLU-945, ClinicalTrials.gov: small cell lung cancer EGFR, ClinicalTrials.gov: small cell lung cancer osimertinib
- ⬜ **Gaps / irrelevant:** NCBI Gene, PubMed: AXL EMT bypass resistance EGFR inhibitor lung cancer single cell spatial transcriptomics, PubMed: fourth generation EGFR inhibitor BLU-945 BBT-176 clinical trial C797S, Reactome: EGFR

### Claim claim_4 — `computational`
> Amivantamab plus chemotherapy vs.
- ✅ **Supporting:** ClinicalTrials.gov: non-small cell lung cancer BLU-945, ClinicalTrials.gov: non-small cell lung cancer EGFR, ClinicalTrials.gov: non-small cell lung cancer osimertinib, ClinicalTrials.gov: small cell lung cancer BLU-945, ClinicalTrials.gov: small cell lung cancer EGFR, ClinicalTrials.gov: small cell lung cancer osimertinib
- ⬜ **Gaps / irrelevant:** NCBI Gene, PubMed: AXL EMT bypass resistance EGFR inhibitor lung cancer single cell spatial transcriptomics, PubMed: fourth generation EGFR inhibitor BLU-945 BBT-176 clinical trial C797S, Reactome: EGFR

### Claim claim_5 — `computational`
> chemotherapy as first-line treatment in Chinese mainland patients with EGFR exon 20 insertion non-small cell lung cancer: Subgroup analysis of the randomized PAPILLON trial..
- ✅ **Supporting:** ClinicalTrials.gov: non-small cell lung cancer BLU-945, ClinicalTrials.gov: non-small cell lung cancer EGFR, ClinicalTrials.gov: non-small cell lung cancer osimertinib, ClinicalTrials.gov: small cell lung cancer BLU-945, ClinicalTrials.gov: small cell lung cancer EGFR, ClinicalTrials.gov: small cell lung cancer osimertinib
- ⬜ **Gaps / irrelevant:** NCBI Gene, PubMed: AXL EMT bypass resistance EGFR inhibitor lung cancer single cell spatial transcriptomics, PubMed: fourth generation EGFR inhibitor BLU-945 BBT-176 clinical trial C797S, Reactome: EGFR

### Claim claim_6 — `⚠ no efficacy claim`
> The remaining scientific work is to resolve mechanism details, response or resistance biology, safety liabilities, and patient-selection strategy
- ✅ **Supporting:** ClinicalTrials.gov: non-small cell lung cancer BLU-945, ClinicalTrials.gov: non-small cell lung cancer EGFR, ClinicalTrials.gov: non-small cell lung cancer osimertinib, ClinicalTrials.gov: small cell lung cancer BLU-945, ClinicalTrials.gov: small cell lung cancer EGFR, ClinicalTrials.gov: small cell lung cancer osimertinib
- ⬜ **Gaps / irrelevant:** NCBI Gene, PubMed: AXL EMT bypass resistance EGFR inhibitor lung cancer single cell spatial transcriptomics, PubMed: fourth generation EGFR inhibitor BLU-945 BBT-176 clinical trial C797S, Reactome: EGFR


## Evidence Coverage Matrix

Coverage score: `1.0` (8 covered, 0 partial, 0 missing)

| Requirement | Status | Matched sources |
| --- | --- | --- |
| Literature evidence | `covered` | PubMed: EGFR mutant NSCLC lineage transformation small cell squamous osimertinib resistance biopsy, PubMed: EGFR non-small cell lung cancer failed trial, PubMed: EGFR non-small cell lung cancer not associated, PubMed: osimertinib acquired resistance mechanisms EGFR C797S MET amplification NSCLC ctDNA |
| Target-disease association | `covered` | ToolUniverse: OpenTargets_get_associated_targets_by_disease_efoId, ToolUniverse: OpenTargets_get_disease_id_description_by_name, ToolUniverse: OpenTargets_get_drug_chembId_by_generic_name |
| Clinical or trial context | `covered` | ClinicalTrials.gov: non-small cell lung cancer BLU-945, ClinicalTrials.gov: non-small cell lung cancer EGFR, ClinicalTrials.gov: non-small cell lung cancer osimertinib, ClinicalTrials.gov: small cell lung cancer BLU-945, ClinicalTrials.gov: small cell lung cancer EGFR, ClinicalTrials.gov: small cell lung cancer osimertinib |
| Safety and toxicity context | `covered` | openFDA adverse events: BBT-176, openFDA adverse events: BLU-945, openFDA adverse events: osimertinib |
| Mechanistic pathway evidence | `covered` | PubMed: EGFR mutant NSCLC lineage transformation small cell squamous osimertinib resistance biopsy, PubMed: osimertinib acquired resistance mechanisms EGFR C797S MET amplification NSCLC ctDNA, ToolUniverse: OpenTargets_get_associated_targets_by_disease_efoId, ToolUniverse: OpenTargets_get_disease_id_description_by_name, ToolUniverse: OpenTargets_get_drug_chembId_by_generic_name |
| Contradictions or missing evidence | `covered` | ClinicalTrials.gov: non-small cell lung cancer BLU-945, ClinicalTrials.gov: non-small cell lung cancer EGFR, ClinicalTrials.gov: small cell lung cancer BLU-945, ClinicalTrials.gov: small cell lung cancer EGFR, PubMed: EGFR non-small cell lung cancer failed trial, PubMed: EGFR non-small cell lung cancer not associated |
| Cell-state or lineage assay evidence | `covered` | PubMed: EGFR mutant NSCLC lineage transformation small cell squamous osimertinib resistance biopsy |
| Fusion and copy-number detection | `covered` | ClinicalTrials.gov: non-small cell lung cancer BLU-945, ClinicalTrials.gov: non-small cell lung cancer EGFR, ClinicalTrials.gov: non-small cell lung cancer osimertinib, ClinicalTrials.gov: small cell lung cancer BLU-945, ClinicalTrials.gov: small cell lung cancer EGFR, ClinicalTrials.gov: small cell lung cancer osimertinib |

## Candidate Intervention Summary

PubChem/literature candidate records were found, but none are asserted as clinically effective.

## Evidence

### Evidence Summary Table

| Source | Label | Score | Evidence |
| --- | --- | --- | --- |
| NCBI Gene | strong_support | 0.82 | NCBI Gene EGFR: The protein encoded by this gene is a transmembrane glycoprotein that is a member of the protein kinase superfamily. This protein is a receptor for members of the epidermal growth factor family. EGFR is a cell surface protein that binds to epidermal growth factor, thus inducing recep |
| NCBI Gene | irrelevant | 0.31 | NCBI Gene NSCLC: NCBI Gene returned a live gene record. |
| Reactome: EGFR | irrelevant | 0.31 | Reactome returned pathway/mechanism records: . |
| PubMed: fourth generation EGFR inhibitor BLU-945 BBT-176 clinical trial C797S | irrelevant | 0.1 | PubMed returned live literature search results for fourth generation EGFR inhibitor BLU-945 BBT-176 clinical trial C797S. |
| Reactome: NSCLC | irrelevant | 0.31 | Reactome returned pathway/mechanism records: . |
| Reactome: EGFR signaling pathway | irrelevant | 0.31 | Reactome returned pathway/mechanism records: . |
| ClinicalTrials.gov: non-small cell lung cancer EGFR | strong_support | 0.82 | ClinicalTrials.gov returned translational study records: Resistance to the Tyrosine Kinase Inhibitor Osimertinib and Pharmacokinetics in Non-small Cell Lung Cancer (ACTIVE_NOT_RECRUITING, phase not listed); Assessing an Oral Janus Kinase Inhibitor, AZD4205, in Combination With Osimertinib in Patient |
| ClinicalTrials.gov: non-small cell lung cancer BLU-945 | weak_support | 0.65 | ClinicalTrials.gov returned translational study records: (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC (TERMINATED, PHASE1) |
| PubMed: EGFR mutant NSCLC lineage transformation small cell squamous osimertinib resistance biopsy | mechanistic_relevance | 0.62 | Comprehensive molecular characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiation.; Paired genomic analysis of squamous cell carcinoma transformed from EGFR-mutated lung adenocarcinoma. |
| Reactome: MET-HGF signaling | irrelevant | 0.31 | Reactome returned pathway/mechanism records: . |
| ClinicalTrials.gov: non-small cell lung cancer osimertinib | strong_support | 0.82 | ClinicalTrials.gov returned translational study records: Resistance to the Tyrosine Kinase Inhibitor Osimertinib and Pharmacokinetics in Non-small Cell Lung Cancer (ACTIVE_NOT_RECRUITING, phase not listed); Assessing an Oral Janus Kinase Inhibitor, AZD4205, in Combination With Osimertinib in Patient |
| ClinicalTrials.gov: small cell lung cancer osimertinib | strong_support | 0.82 | ClinicalTrials.gov returned translational study records: Resistance to the Tyrosine Kinase Inhibitor Osimertinib and Pharmacokinetics in Non-small Cell Lung Cancer (ACTIVE_NOT_RECRUITING, phase not listed); Assessing an Oral Janus Kinase Inhibitor, AZD4205, in Combination With Osimertinib in Patient |
| ClinicalTrials.gov: small cell lung cancer BLU-945 | weak_support | 0.65 | ClinicalTrials.gov returned translational study records: (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC (TERMINATED, PHASE1) |
| ClinicalTrials.gov: small cell lung cancer EGFR | strong_support | 0.82 | ClinicalTrials.gov returned translational study records: Resistance to the Tyrosine Kinase Inhibitor Osimertinib and Pharmacokinetics in Non-small Cell Lung Cancer (ACTIVE_NOT_RECRUITING, phase not listed); Assessing an Oral Janus Kinase Inhibitor, AZD4205, in Combination With Osimertinib in Patient |
| openFDA adverse events: osimertinib | safety_concern | 0.72 | openFDA returned 7990 matching adverse-event reports. Common returned reaction terms include: Acute pulmonary oedema; Death; Femur fracture; Hyponatraemia; Multiple fractures. These are safety signals, not incidence rates or causal proof. |
| ToolUniverse: OpenTargets_get_disease_id_description_by_name | weak_support | 0.62 | OpenTargets_get_disease_id_description_by_name returned OpenTargets search hits: non-small cell lung carcinoma: A group of at least three distinct histological types of lung cancer, including non-small cell squamous cell carcinoma, adenocarcinoma, and large cell carcinoma. Non-small cell lung carcin |
| ToolUniverse: OpenTargets_get_drug_chembId_by_generic_name | weak_support | 0.62 | OpenTargets_get_drug_chembId_by_generic_name returned OpenTargets search hits: OSIMERTINIB: Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for non-small cell lung carcinoma and neoplasm and 9 investigational indications.; OSIMERTINIB MESYLATE |
| PubMed: AXL EMT bypass resistance EGFR inhibitor lung cancer single cell spatial transcriptomics | irrelevant | 0.1 | PubMed returned live literature search results for AXL EMT bypass resistance EGFR inhibitor lung cancer single cell spatial transcriptomics. |
| ToolUniverse: OpenTargets_get_disease_id_description_by_name | weak_support | 0.62 | OpenTargets_get_disease_id_description_by_name returned OpenTargets search hits: small cell lung carcinoma: Small cell lung cancer (SCLC) is a highly aggressive malignant neoplasm, accounting for 10-15% of lung cancer cases, characterized byrapid growth, and early metastasis. SCLC usually manifests  |
| PubMed: osimertinib acquired resistance mechanisms EGFR C797S MET amplification NSCLC ctDNA | strong_support | 0.78 | Long-Term Impact of First-Line Amivantamab Plus Lazertinib Versus Osimertinib on Mechanisms of Acquired Resistance in MARIPOSA: A Brief Report. |
| ToolUniverse: OpenTargets_get_drug_chembId_by_generic_name | irrelevant | 0.31 | OpenTargets_get_drug_chembId_by_generic_name returned OpenTargets search hits: TIGOZERTINIB: Small molecule drug with a maximum clinical stage of Phase 1 2 (across all indications), with 5 investigational indications. |
| ToolUniverse: OpenTargets_get_drug_chembId_by_generic_name | irrelevant | 0.31 | OpenTargets_get_drug_chembId_by_generic_name returned ToolUniverse/OpenTargets evidence: None |
| ToolUniverse: OpenTargets_get_drug_chembId_by_generic_name | irrelevant | 0.31 | OpenTargets_get_drug_chembId_by_generic_name returned OpenTargets search hits: SAVOLITINIB: Small molecule drug with a maximum clinical stage of Phase 3 (across all indications), with 9 investigational indications. |
| ToolUniverse: OpenTargets_get_drug_chembId_by_generic_name | weak_support | 0.62 | OpenTargets_get_drug_chembId_by_generic_name returned OpenTargets search hits: AMIVANTAMAB: Antibody drug with a maximum clinical stage of Approval (across all indications), with an approval for neoplasm and non-small cell lung carcinoma and 4 investigational indications. |
| ToolUniverse: OpenTargets_get_drug_chembId_by_generic_name | weak_support | 0.62 | OpenTargets_get_drug_chembId_by_generic_name returned OpenTargets search hits: CAPMATINIB: Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for non-small cell lung carcinoma and neoplasm and 5 investigational indications.; CAPMATINIB HYDROCHLOR |
| openFDA adverse events: BLU-945 | safety_concern | 0.72 | openFDA returned None matching adverse-event reports. Common returned reaction terms include: none in returned reports. These are safety signals, not incidence rates or causal proof. |
| openFDA adverse events: BBT-176 | safety_concern | 0.72 | openFDA returned None matching adverse-event reports. Common returned reaction terms include: none in returned reports. These are safety signals, not incidence rates or causal proof. |
| PubChem candidate lookup | mechanistic_relevance | 0.46 | PubChem returned candidate/intervention records for: osimertinib, BLU-945, BBT-176, savolitinib, capmatinib. |
| ToolUniverse: OpenTargets_get_associated_targets_by_disease_efoId | strong_support | 0.82 | OpenTargets_get_associated_targets_by_disease_efoId returned 13431 associated targets for non-small cell lung carcinoma; top retrieved targets: EGFR association score 0.888; KRAS association score 0.842; ALK association score 0.812; ERBB2 association score 0.811 |
| ToolUniverse: OpenTargets_get_associated_targets_by_disease_efoId | strong_support | 0.82 | OpenTargets_get_associated_targets_by_disease_efoId returned 420 associated targets for non-small cell squamous lung carcinoma; top retrieved targets: EGFR association score 0.468; ALK association score 0.375; VEGFA association score 0.373; CRTC1 association score 0.371 |
| PubMed: EGFR non-small cell lung cancer failed trial | strong_support | 0.78 | Immunotherapy for TKI-resistant, EGFR L858R-mutated non-small cell lung cancer: a systematic review and meta-analysis of randomized and single-arm studies.; Advances in the research on radiotherapy for lung cancer: a 2025 review.; Role of EGFR-TKIs in Nonmetastatic Epidermal Growth Factor Receptor-M |
| PubMed: EGFR non-small cell lung cancer not associated | strong_support | 0.78 | Amivantamab plus chemotherapy vs. chemotherapy as first-line treatment in Chinese mainland patients with EGFR exon 20 insertion non-small cell lung cancer: Subgroup analysis of the randomized PAPILLON trial.; Compound EGFR mutations are predominantly PACC (P-loop and alpha-C helix compressing) mutat |

## Citations and Retrieved Records

- [EGFR](https://www.ncbi.nlm.nih.gov/gene/1956) (gene_id: 1956)
- [Comprehensive molecular characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiation.](https://pubmed.ncbi.nlm.nih.gov/34656143/) (pmid: 34656143; journal: Journal of hematology & oncology; pubdate: 2021 Oct 16)
- [Paired genomic analysis of squamous cell carcinoma transformed from EGFR-mutated lung adenocarcinoma.](https://pubmed.ncbi.nlm.nih.gov/31319998/) (pmid: 31319998; journal: Lung cancer (Amsterdam, Netherlands); pubdate: 2019 Aug)
- [Long-Term Impact of First-Line Amivantamab Plus Lazertinib Versus Osimertinib on Mechanisms of Acquired Resistance in MARIPOSA: A Brief Report.](https://pubmed.ncbi.nlm.nih.gov/42061572/) (pmid: 42061572; journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer; pubdate: 2026 Apr 28)
- [osimertinib](https://pubchem.ncbi.nlm.nih.gov/compound/71496458) (cid: 71496458)
- [BLU-945](https://pubchem.ncbi.nlm.nih.gov/compound/156538665) (cid: 156538665)
- [BBT-176](https://pubchem.ncbi.nlm.nih.gov/compound/142497307) (cid: 142497307)
- [savolitinib](https://pubchem.ncbi.nlm.nih.gov/compound/68289010) (cid: 68289010)
- [capmatinib](https://pubchem.ncbi.nlm.nih.gov/compound/25145656) (cid: 25145656)
- [Immunotherapy for TKI-resistant, EGFR L858R-mutated non-small cell lung cancer: a systematic review and meta-analysis of randomized and single-arm studies.](https://pubmed.ncbi.nlm.nih.gov/42039162/) (pmid: 42039162; journal: Frontiers in immunology; pubdate: 2026)
- [Advances in the research on radiotherapy for lung cancer: a 2025 review.](https://pubmed.ncbi.nlm.nih.gov/41982692/) (pmid: 41982692; journal: Translational lung cancer research; pubdate: 2026 Mar 23)
- [Role of EGFR-TKIs in Nonmetastatic Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Comprehensive Review.](https://pubmed.ncbi.nlm.nih.gov/41730152/) (pmid: 41730152; journal: JCO oncology practice; pubdate: 2026 Feb 23)

## Limitations

- Live public database records support hypothesis generation but do not validate efficacy.
- No clinical efficacy or safety claim is made.
- Compound specificity and translational risk remain unresolved.
- Evidence scoring is rule-based and should be calibrated with a trained biomedical evidence model.
- LLM hypothesis synthesis was unstructured; raw response is preserved in provenance.

## Scientist Panel Debate

*Collaboration model: `parallel_llm_scientist_panel`*

### mechanism_agent — ✅ support with limits
*Discipline: disease mechanism and causal pathway biology*

EGFR-mutant NSCLC acquired resistance after first-line osimertinib is mechanistically heterogeneous; causal pathway dissection requires systematic molecular stratification before any therapeutic prioritization

**Concerns:**
- Biopsy sampling bias: single-site post-progression biopsy misses spatial heterogeneity and may misclassify dominant resistance mechanism
- ctDNA VAF thresholds for MET amplification calling are not standardized across platforms, inflating false-positive bypass resistance calls
- Lineage transformation frequency is likely underestimated without systematic re-biopsy protocols; SCLC transformation requires IHC not captured by liquid biopsy alone
- Distinguishing driver from bystander alterations (e.g., KRAS co-mutation) requires functional validation not yet available for most clinical cohorts

**Requested follow-ups:**
- Paired pre/post-progression biopsy with concurrent ctDNA to phase C797S/T790M in cis vs trans and quantify MET copy number by FISH
- Single-cell RNA-seq on post-progression tumor to detect AXL-high EMT or neuroendocrine lineage shift orthogonal to genomic profiling
- CSF osimertinib level measurement in CNS-only progressors to distinguish pharmacokinetic from genomic sanctuary resistance

### tooluniverse_agent — ✅ support with limits
*Discipline: ToolUniverse/OpenTargets target and intervention evidence*

EGFR is a high-confidence, clinically validated driver in NSCLC with well-documented acquired resistance mechanisms after osimertinib; the research priority is mechanistic stratification of resistance, not target validation

**Concerns:**
- Resistance mechanism frequencies vary by prior therapy line and patient ancestry; MARIPOSA data may not generalize to all osimertinib-treated populations
- Small-cell and squamous lineage transformation are underdetected without tissue biopsy; ctDNA alone insufficient
- CNS sanctuary pharmacokinetics are poorly captured in systemic resistance cohorts
- Bystander alterations (e.g., KRAS co-mutations) may confound driver resistance assignment without functional validation

**Requested follow-ups:**
- Paired pre/post-osimertinib biopsy plus ctDNA clone phasing for C797S cis-vs-trans in prospective cohort
- Single-cell or spatial transcriptomics to quantify AXL-high EMT and lineage plasticity frequency
- MET and ERBB2 copy-number profiling by FISH alongside NGS to resolve amplification thresholds

### literature_agent — ✅ support with limits
*Discipline: biomedical literature and citation grounding*

The acquired-resistance landscape after first-line osimertinib in EGFR-mutant NSCLC is well-characterized in peer-reviewed literature and warrants a structured, mechanism-stratified research strategy rather than a single-target hypothesis.

**Concerns:**
- Hypothesis card frames EGFR as insufficiently established which contradicts the strong OpenTargets and guideline evidence
- Resistance frequency estimates vary widely across studies due to biopsy timing and assay heterogeneity
- CNS sanctuary and exposure-limited resistance remain underrepresented in ctDNA-based cohorts
- Small-cell and squamous transformation frequencies may be underestimated without systematic re-biopsy protocols

**Requested follow-ups:**
- Provide paired pre/post-osimertinib biopsy cohort data with allele-frequency thresholds distinguishing driver from subclonal resistance
- Clarify C797S cis-vs-trans phasing data relative to residual T790M in post-first-line osimertinib samples
- Specify trial-design failure gates for fourth-generation EGFR inhibitor combinations before efficacy claims

### molecule_agent — ✅ support with limits
*Discipline: candidate intervention and chemistry review*

EGFR C797S and bypass mechanisms (MET/HER2 amplification, lineage plasticity) are the dominant post-osimertinib resistance drivers; fourth-generation inhibitors and rational combinations are the priority research frontier

**Concerns:**
- C797S cis/trans phasing requires allele-specific ctDNA or single-cell sequencing not routinely available
- Fourth-generation EGFR inhibitors lack Phase 3 efficacy/safety data; preclinical selectivity claims need clinical validation
- Lineage transformation frequency may be underestimated due to biopsy site selection bias
- KRAS/NRAS co-mutations as true bypass vs bystander clones not yet resolved in prospective cohorts

**Requested follow-ups:**
- Paired pre/post-osimertinib biopsy with single-cell RNA-seq to distinguish EMT-high vs lineage-transformed subclones
- Allele-phasing ctDNA assay to determine C797S cis vs trans frequency at progression
- Prospective MET FISH + plasma MET copy-number concordance study to define actionable amplification threshold

### safety_agent — 🔄 revise
*Discipline: clinical safety and translation risk*

Safety agent challenging overclaims in post-osimertinib resistance research strategy

**Concerns:**
- Cis/trans phasing of T790M+C797S requires allele-specific sequencing not routinely available; misclassification risk is high
- Bypass resistance drivers (MET, HER2 amp) may be subclonal and not uniformly targetable; treating based on ctDNA detection alone risks overtreatment
- CNS sanctuary pharmacology data for fourth-gen inhibitors is largely preclinical; CNS efficacy claims are premature
- Combination strategies amplify toxicity risk; no randomized safety data yet for most fourth-gen plus MET inhibitor regimens

**Requested follow-ups:**
- Require paired pre/post biopsy with allele-specific phasing before classifying C797S cis vs trans in any trial
- Define minimum VAF threshold and orthogonal confirmation for ctDNA-detected bypass drivers before treatment allocation
- Mandate histologic re-biopsy protocol with SCLC/squamous IHC panel as failure gate in lineage-transformation arm

### omics_agent — ✅ support with limits
*Discipline: omics, pathway, and perturbation evidence*

Pathway and cellular evidence strongly supports EGFR-driven resistance mechanisms after first-line osimertinib, with bypass and lineage-plasticity routes equally well-documented; the hypothesis card understates the mechanistic maturity of this field.

**Concerns:**
- Cis vs trans phasing of T790M/C797S requires allele-specific ctDNA or single-cell sequencing not routinely performed
- Lineage transformation frequency is likely underestimated due to biopsy sampling bias
- Bypass resistance drivers (RET, ALK fusions) may be bystander events without functional validation in isogenic models
- CNS pharmacokinetic sanctuary resistance is mechanistically distinct but conflated with molecular resistance in most datasets

**Requested follow-ups:**
- Paired pre/post biopsy with single-cell RNA-seq to distinguish EMT-state from true small-cell transformation
- Allele-phasing ctDNA assays to resolve C797S cis/trans configuration before combination TKI selection
- Isogenic EGFR-mutant cell line panel with introduced bypass alterations to rank driver vs bystander status

### critic_agent — 🔄 revise
*Discipline: skeptical scientific review*

The hypothesis card correctly identifies EGFR as a high-confidence, clinically validated target in NSCLC, but the framing as 'early or insufficiently established' is internally contradictory given the cited evidence. The resistance-mechanism synthesis task is scientifically sound and necessary, but several critical analytical gaps undermine its audit-readiness.

**Concerns:**
- Hypothesis card framing ('early or insufficiently established') directly contradicts the 0.888 OpenTargets association score and decades of phase III trial data-this logical inconsistency must be resolved before the card is audit-ready
- No paired pre/post-osimertinib biopsy cohort with allele-phasing data (cis vs trans C797S/T790M) is cited; without this, ranked resistance mechanism frequencies are speculative
- CNS sanctuary and exposure-limited resistance hypotheses lack pharmacokinetic/pharmacodynamic evidence linkage in the current evidence digest-CSF drug level data are absent
- Bypass resistance drivers (RET/ALK fusions, BRAF V600E) are listed without incidence denominators from osimertinib-specific post-progression cohorts, risking overweighting rare events

**Requested follow-ups:**
- Provide prospective or large retrospective cohort data with allele-phasing (cis/trans C797S) frequencies specifically from first-line osimertinib progressors, not pooled TKI lines
- Cite CSF osimertinib concentration studies or CNS progression-specific PK data to substantiate the exposure-limited resistance hypothesis
- Define failure gates and minimum detectable effect sizes for each proposed next experiment before ranking them-current ranking lacks statistical power justification

### PI Adjudication

{"accepted_claims":["EGFR is a high-confidence, guideline-validated driver in NSCLC; open questions concern resistance mechanism stratification, not target discovery","C797S cis-vs-trans phasing with T790M is mechanistically decisive and requires allele-phasing assays beyond standard NGS","MET amplification and ERBB2 amplification are leading bypass resistance nodes after osimertinib per MARIPOSA ctDNA data (PMID 42061572), pending standardized copy-number thresholds","Lineage plasticity (SCLC transformation, AXL-high EMT) requires orthogonal tissue-based assays and is likely underestimated by ctDNA-only cohorts","CNS sanctuary progression may reflect pharmacokinetic rather than genomic resistance and requires CSF drug-level measurement for mechanism attribution"],"softened_or_rejected_claims":["REJECTED: Hypothesis card framing of EGFR as 'early or insufficiently established' contradicts OpenTargets score 0.888 and ASCO 2026 guideline endorsement","SOFTENED: MET amplification as 'dominant' bypass node is plausible but not definitive; platform-specific VAF thresholds and FISH confirmation are required before ranking","SOFTENED: MARIPOSA resistance frequencies should not be generali


## Proposed Next Experiments

### Experiment 1: Resolve the highest-uncertainty EGFR / non-small cell lung cancer evidence gap with targeted Open Targets, literature, clinical-precedence, and safety review
**Type:** `computational` | **Cost:** `low` | **Feasibility:** `high` | **Expected information gain:** `high`

**Decision gate:** Proceed only if the result adds evidence not already represented in the run.

**Success criteria:**
- New evidence changes the confidence, claim boundary, or next experiment.

**Failure modes to watch:**
- The result is indirect, non-specific, or does not change the claim boundary.

**Gate score:** `0.711` (usable)

### Experiment 2: Repair unsupported claim links or soften claim boundaries
**Type:** `computational` | **Cost:** `low-medium` | **Feasibility:** `high` | **Expected information gain:** `high`

**Decision gate:** Advance the hypothesis only if this resolves: claim_graph_evidence_gap

**Success criteria:**
- claim-specific supporting evidence or explicit claim softening

**Failure modes to watch:**
- The result is indirect, non-specific, or does not change the claim boundary.

**Gate score:** `0.691` (usable)

### Experiment 3: Resolve evidence gap: reviewer_high_severity_concern
**Type:** `computational` | **Cost:** `low-medium` | **Feasibility:** `high` | **Expected information gain:** `high`

**Decision gate:** Advance the hypothesis only if this resolves: reviewer_high_severity_concern

**Success criteria:**
- direct evidence resolving reviewer-identified overclaim or contradiction

**Failure modes to watch:**
- The result is indirect, non-specific, or does not change the claim boundary.

**Gate score:** `0.691` (usable)

### Experiment 4: Resolve evidence gap: evidence_relevance_noise
**Type:** `computational` | **Cost:** `low-medium` | **Feasibility:** `high` | **Expected information gain:** `high`

**Decision gate:** Advance the hypothesis only if this resolves: evidence_relevance_noise

**Success criteria:**
- higher-precision retrieval with irrelevant records filtered from the claim boundary

**Failure modes to watch:**
- The result is indirect, non-specific, or does not change the claim boundary.

**Gate score:** `0.691` (usable)

### Experiment 5: Rank candidate interventions by EGFR mutant selectivity, wild-type sparing, CNS penetration, acquired-resistance profile, and ADMET liabilities
**Type:** `computational` | **Cost:** `low-medium` | **Feasibility:** `medium` | **Expected information gain:** `high`

**Decision gate:** Proceed only if the result adds evidence not already represented in the run.

**Success criteria:**
- New evidence changes the confidence, claim boundary, or next experiment.

**Failure modes to watch:**
- The result is indirect, non-specific, or does not change the claim boundary.

**Gate score:** `0.636` (usable)

### Experiment 6: Run safety-first triage before efficacy assays: exposure margins, off-target biology, and disease-context tolerability
**Type:** `computational_plus_wet_lab` | **Cost:** `medium` | **Feasibility:** `medium` | **Expected information gain:** `high`

**Decision gate:** Proceed only if the result adds evidence not already represented in the run.

**Success criteria:**
- New evidence changes the confidence, claim boundary, or next experiment.

**Failure modes to watch:**
- The result is indirect, non-specific, or does not change the claim boundary.

**Gate score:** `0.615` (usable)


## Critique and Refinement

**Severity:** `high`

The hypothesis card contains a fundamental internal contradiction: it frames EGFR as 'early or insufficiently established' for NSCLC, yet the assembled evidence overwhelmingly demonstrates the opposite. EGFR has an OpenTargets association score of 0.888 for non-small cell lung carcinoma (the highest among 13,431 associated targets), multiple FDA-approved TKIs (osimertinib, erlotinib, gefitinib, afatinib, dacomitinib), an approved bispecific antibody (amivantamab), an ASCO Living Guideline (2026.3.1) explicitly covering EGFR-driver NSCLC, and decades of Phase III randomized controlled trial data. Characterizing this as 'early or insufficiently established' is factually incorrect and potentially misleading. Secondary overclaims include: (1) the readiness score of 89/100 labeled 'validation_ready' is inconsistent with the stated framing of insufficient establishment; (2) the NCBI Gene evidence is scored 'strong_support' (0.82) yet classified as 'tier_unknown' with 'low hierarchy confidence,' creating an internal scoring contradiction; (3) the NSCLC entry is treated as a gene lookup failure rather than correctly identified as a disease entity, representing a methodological error; (4) the PubMed query returning zero results for BLU-945/BBT-176/C797S fourth-generation inhibitors is presented as a gap without acknowledging that published clinical data for these agents does exist in the literature; (5) safety liabilities are listed as unresolved despite extensive openFDA adverse event data and published toxicity profiles for approved agents; (6) the claim that 'patient-selection strategy' requires resolution ignores established companion diagnostic frameworks (cobas EGFR Mutation Test, FoundationOne CDx) with regulatory approval.

**Recommended fix:** Reframe the hypothesis to accurately reflect EGFR's status as a clinically validated, guideline-endorsed oncology target in NSCLC. The scientific work to be done should be scoped specifically to: (a) fourth-generation inhibitor development for C797S and other tertiary resistance mutations, (b) mechanisms of lineage plasticity resistance (SCLC transformation, squamous transition), (c) combination strategies for immunotherapy in EGFR-mutant NSCLC, and (d) exon 20 insertion-specific therapeutic optimization. Evidence tier classifications must be corrected: EGFR-NSCLC association should be classified as Tier 1 (clinical evidence with regulatory approval), not tier_unknown. The NSCLC query error must be corrected to use disease ontology identifiers rather than gene symbol lookups. Scoring contradictions between label ('strong_support') and hierarchy_confidence ('low') must be resolved. The framing language 'early or insufficiently established hypothesis' must be removed entirely as it contradicts all assembled evidence.

## Guardrails

- Candidate hypothesis only.
- Target-disease or clinical-precedence evidence must be separated from efficacy and safety claims.
- Requires experimental validation before clinical interpretation.

---
*Generated by AutoScientist. Candidate hypothesis only. Requires experimental validation.*
